findmyKOL
Clinical trialNCT01273610Active, not recruitingPhase 2Interventional

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

SponsorCity of Hope Medical CenterEnrollment40Breast NeoplasmsGeriatric Health ServicesHER2/Neu Positive
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • City of Hope Medical Center

    Duarte, California, United States

  • City of Hope Antelope Valley

    Lancaster, California, United States

  • South Pasadena Cancer Center

    Pasadena, California, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, United States

  • Lineberger Comprehensive Cancer Center, University of North Carolina

    Chapel Hill, North Carolina, United States

  • Duke University Medical Center

    Durham, North Carolina, United States

  • Case Western Reserve University

    Cleveland, Ohio, United States

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 Apr 2011
Primary completion
22 Feb 2018
Completion
20 Apr 2027
Last update posted
25 Jun 2026
Registered enrollment
40
Registry id
NCT01273610

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.